WinstonWınston
Prestige Consumer Healthcare logo

Prestige Consumer Healthcare

PBH
53
Medical - Distribution · Healthcare
Price
$49.92
-0.68 (-1.34%)
Market Cap
$2.36B
Winston Score
53
Winston is curious
Mixed quality — meaningful strengths and weaknesses.

Share count falling — buybacks

4.2% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 50.8M (2022) → 48.7M (2026)

Prestige Consumer Healthcare sells over-the-counter health and wellness products that people buy without a prescription. Its brands include Clear Eyes eye drops, Monistat, BC Powder, Chloraseptic, and Dramamine, among others. The company focuses entirely on self-care products sold directly to everyday consumers through drugstores, grocery stores, and mass retailers like Walmart and CVS.

The company makes money by selling branded consumer health products, relying on brand recognition to charge slightly higher prices than generic alternatives. It operates primarily in the United States, with a smaller international presence, and generates roughly $1.1 billion in annual revenue. Its main competitive advantage is owning a portfolio of trusted, well-known brand names that consumers repeatedly buy out of habit — but the key risk is that private-label store brands continue gaining shelf space and price-conscious shoppers trade down, pressuring both sales volume and margins over time.

Winston Score History

Politician Trades

3 trades / 12mo

1 Congressional buy and 2 sells on PBH in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-5.1% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+12.9% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

1.4%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$64M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Prestige Consumer Healthcare's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
50.0%
Healthy — 50.0% gross margin
Operating Margin
26.8%
Excellent — 26.8% operating margin
ROCE
3.9%
Weak — 3.9% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+3.2%
Slow sales growth (3.2% YoY)
EPS YoY
-6.8%
Earnings shrinking (-6.8% YoY)

Slight earnings drop. Typical near a cyclical low.

EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
129%
Turns 129% of profit into real cash
FCF Margin
20.6%
Converts sales into free cash efficiently (20.6%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.03
Conservative — low debt load (0.03)
Interest Cover
7.60x
Adequate interest coverage (7.6x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
12.5x
Attractive valuation — P/E 12.5

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
+3.3
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (12.5 → 9.2)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial